Antihormonal Cancer Therapy is a treatment with drugs, surgery, or radiation in order to block the production or action of a hormone. Antihormone therapy may be used in cancer treatment because certain hormones are able to stimulate the growth of some types of tumors.
In 2018, the global Antihormonal Cancer Therapies market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Antihormonal Cancer Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Antihormonal Cancer Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

AstraZeneca
Novartis
Pfizer
Sanofi
Takeda
Roche
Amgen
Samyang Biopharmaceuticals
Tolmar
Bluebird Bio
Bristol-Myers Squibb
Exelixis
Guardant Health
Illumina

Market segment by Type, the product can be split into

Radiations
Drugs
Surgeries
Others

Market segment by Application, split into

Breast Cancer
Prostate Cancer
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Antihormonal Cancer Therapies status, future forecast, growth opportunity, key market and key players.
To present the Antihormonal Cancer Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Antihormonal Cancer Therapies are as follows:
History Year: 2014-2018

Base Year:

2018

Estimated Year:

2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.